Cepheid has obtained CE mark for its molecular diagnostic test to qualitatively identify SARS-CoV-2, influenza virus and respiratory syncytial virus (RSV) from one patient sample.
The Xpert Xpress CoV-2/Flu/RSV plus offers a third gene target for detecting SARS-CoV-2 to boost the potential for identifying any viral mutations in the future.
Several SARS-CoV-2 variants have been detected across the globe over the course of the Covid-19 pandemic.
As viruses continuously mutate, novel viral variants are anticipated to continue to develop over time.
